Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its AI-driven discovery platform, has closed an oversubscribed $50 million extension to its Series B financing, which was led by new investors Mubadala Capital and Exor Ventures, with participation from Qatar Investment Authority (QIA), and existing investors Abingworth, Illumina Ventures, Nexus Venture Partners, Coatue, and Tao Capital Partners.   The extension adds to an oversubscribed $100 millio...